Turning everyday results to AI powered insights in Kidney Care
:quality(90)/)
By combining AI with routine tests, Roche helps physicians identify patients at risk of kidney function decline early on, enabling more informed and confident decision-making.
Chronic kidney disease (CKD) is a growing global health concern, affecting over 700 million people worldwide. It often progresses without symptoms until advanced stages, when kidney function is already severely compromised.
To help address this challenge, Roche is combining AI and automation with traditional biomarkers to improve the management of CKD.
In early disease stages, a CE-marked AI-based solution helps predict the risk of kidney function decline, not only in people already diagnosed with CKD, but also in those at risk due to conditions such as diabetes or hypertension.
In later stages, a more widely used and globally validated CE-marked algorithm solution supports patient management.
Supporting clinicians to make informed decisions on patient management
Roche’s vision is to help clinicians turn insights into actionable, guideline-aligned care. Digital health innovations — such as AI-driven risk stratification and advanced data insights — are now helping physicians better manage risk across the CKD pathway. Clinicians can then act earlier, tailor treatment, and help prevent complications before they occur. For patients, this means fewer hospitalizations and a better quality of life.
Routine data, smarter insights
:quality(90)/)
The launch of the Chronic Kidney Disease algorithm panel, is a major step forward in the fight against this often silent, progressive disease. The panel is designed to support physicians to make more informed decisions and manage patients’ kidney function proactively at every stage of the disease. Most importantly, this now also includes the possibility to assess adults with diabetes and hypertension, who are at elevated risk for kidney function decline and not yet diagnosed with CKD.
The new panel is designed for seamless integration into clinical workflow. It works with routine blood and urine test results, applying AI-based calculations and aligning recommendations with established clinical guidelines. This allows physicians to obtain consistent and reliable insights, supporting more personalized care.
Why it matters
CKD is a global public health challenge, closely linked to diabetes, hypertension, and obesity. Left untreated, it can lead to kidney failure requiring dialysis or transplantation, and it significantly increases the risk of cardiovascular disease and premature mortality.
With earlier detection and proactive care, clinicians can delay or even prevent kidney function decline, improving patient outcomes while reducing the burden on healthcare systems.
Looking ahead
Roche is committed to ongoing investment in diagnostics and digital innovation to help clinicians deliver better patient care every day.
For patients, this means earlier answers, more informed decisions, and better chances at healthier futures.
References
GBD Chronic Kidney Disease Collaboration, Lancet (2020) https://doi.org/10.1016/S0140-6736(20)30045-3
Shlipak, Kidney International (2021) https://doi.org/10.1016/j.kint.2020.10.012
Romagnani, P., Agarwal, R., Chan, J.C.N. et al. Chronic kidney disease. Nat Rev Dis Primers 11, 8 (2025). https://doi.org/10.1038/s41572-024-00589-9
Francis A, Harhay MN, Ong ACM. et al. Chronic kidney disease and the global public health agenda: an international consensus. Nat Rev Nephrol. 2024 Jul;20(7):473-485. doi: 10.1038/s41581-024-00820-6. Epub 2024 Apr 3. PMID: 38570631.